P53 gene replacement for cancer--interactions with DNA damaging agents

Area of Science:

• Oncology
• Gene Therapy
• Cancer Research

Background:

• Unresectable tumors, particularly lung cancers, present a significant challenge in oncology, with conventional therapies like chemotherapy and radiotherapy showing limited efficacy (less than 20% control).
• The tumor suppressor gene p53 plays a crucial role in preventing cancer, and its dysfunction is implicated in many malignancies.

Purpose of the Study:

• To evaluate the safety and efficacy of p53 gene replacement therapy via direct intratumor injection for unresectable tumors.
• To assess the potential of combining p53 gene therapy with conventional treatments like radiotherapy and chemotherapy.

Main Methods:

• Clinical trials involving direct intratumor injection of the p53 gene.
• Monitoring of gene expression post-injection, including the host's immune response to the adeno-viral vector.
• Assessment of tumor response, including regression and stabilization.

Main Results:

• Direct intratumor injection demonstrated low toxicity and was well-tolerated.
• Post-injection p53 gene expression was documented, even with an anti-adenovirus immune response.
• Significant tumor regression or prolonged stabilization was observed in treated patients.

Conclusions:

• P53 gene replacement therapy via direct intratumor injection is a viable and safe strategy for managing unresectable tumors.
• This approach holds potential for enhancing the efficacy of existing treatments like radiotherapy and chemotherapy.
• Future research should focus on developing more efficient vectors, exploring novel therapeutic genes, and optimizing combined modality treatments.